Explore

Trendline Trendline
Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment
Trendline Trendline
Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting

Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting

Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting
Trendline Trendline
OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026
Trendline Trendline
CicadaBio Presents New Data on CC-18 for Muscle-Preservation Weight Loss at ADA 2026

CicadaBio Presents New Data on CC-18 for Muscle-Preservation Weight Loss at ADA 2026

CicadaBio Presents New Data on CC-18 for Muscle-Preservation Weight Loss at ADA 2026
Trendline Trendline
Ascletis Showcases Obesity Treatment Advancements at ADA 2026 Scientific Sessions

Ascletis Showcases Obesity Treatment Advancements at ADA 2026 Scientific Sessions

Ascletis Showcases Obesity Treatment Advancements at ADA 2026 Scientific Sessions
Trendline Trendline
CicadaBio Presents Promising Preclinical Data on Obesity Treatment at ADA 2026

CicadaBio Presents Promising Preclinical Data on Obesity Treatment at ADA 2026

CicadaBio Presents Promising Preclinical Data on Obesity Treatment at ADA 2026
Trendline Trendline
Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study
Trendline Trendline
Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition

Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition

Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition
Trendline Trendline
Roche and Zealand Pharma's Amylin Analog Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Shows Moderate Weight Loss in Phase 2 Study
Trendline Trendline
Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial

Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial

Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial
Trendline Trendline
Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron

Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron

Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron
Trendline Trendline
Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine

Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine

Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine